Columbia Asset Management continued to hold its stake in shares of Sanofi (NYSE:SNY) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,373 shares of the company’s stock at the end of the second quarter. Columbia Asset Management’s holdings in Sanofi were worth $305,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in SNY. LSV Asset Management lifted its holdings in Sanofi by 0.9% during the 1st quarter. LSV Asset Management now owns 139,800 shares of the company’s stock valued at $6,325,000 after purchasing an additional 1,300 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Sanofi by 1.0% during the 1st quarter. Bank of New York Mellon Corp now owns 305,326 shares of the company’s stock valued at $13,816,000 after purchasing an additional 3,013 shares during the last quarter. BNP Paribas Arbitrage SA lifted its holdings in Sanofi by 69.8% during the 1st quarter. BNP Paribas Arbitrage SA now owns 17,692 shares of the company’s stock valued at $801,000 after purchasing an additional 7,275 shares during the last quarter. Karp Capital Management Corp bought a new position in Sanofi during the 1st quarter valued at about $26,174,000. Finally, Sei Investments Co. lifted its holdings in Sanofi by 0.4% during the 1st quarter. Sei Investments Co. now owns 670,240 shares of the company’s stock valued at $30,329,000 after purchasing an additional 2,361 shares during the last quarter. 9.33% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “Sanofi (SNY) Stake Held by Columbia Asset Management” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://sportsperspectives.com/2017/09/11/sanofi-sny-stake-held-by-columbia-asset-management.html.
In related news, major shareholder Sanofi bought 105,820 shares of the company’s stock in a transaction dated Thursday, August 24th. The stock was purchased at an average price of $482.04 per share, with a total value of $51,009,472.80. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.00% of the stock is currently owned by corporate insiders.
SNY has been the subject of several analyst reports. Zacks Investment Research raised shares of Sanofi from a “hold” rating to a “buy” rating and set a $55.00 price target for the company in a report on Friday, June 2nd. BidaskClub downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Friday, June 9th. Argus lifted their price target on shares of Sanofi from $50.00 to $55.00 and gave the company a “buy” rating in a report on Friday, June 9th. Cowen and Company reissued a “market perform” rating and set a $52.00 price target (up from $46.00) on shares of Sanofi in a report on Tuesday, August 1st. Finally, HSBC Holdings plc raised shares of Sanofi from a “reduce” rating to a “hold” rating in a report on Wednesday, August 30th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $54.00.
Sanofi (NYSE SNY) traded down 1.60% during midday trading on Monday, reaching $48.58. 337,349 shares of the company’s stock traded hands. Sanofi has a 52-week low of $36.81 and a 52-week high of $50.24. The company has a market cap of $122.01 billion, a P/E ratio of 11.57 and a beta of 0.88. The stock has a 50-day moving average of $48.21 and a 200 day moving average of $47.17.
Sanofi (NYSE:SNY) last posted its earnings results on Monday, July 31st. The company reported $0.74 EPS for the quarter, hitting analysts’ consensus estimates of $0.74. The firm had revenue of $8.66 billion during the quarter, compared to analysts’ expectations of $8.71 billion. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The business’s revenue for the quarter was down 2.3% compared to the same quarter last year. On average, analysts anticipate that Sanofi will post $3.34 earnings per share for the current fiscal year.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.